305 related articles for article (PubMed ID: 19295632)
1. Selectivity and therapeutic inhibition of kinases: to be or not to be?
Ghoreschi K; Laurence A; O'Shea JJ
Nat Immunol; 2009 Apr; 10(4):356-60. PubMed ID: 19295632
[TBL] [Abstract][Full Text] [Related]
2. JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Garber K
J Natl Cancer Inst; 2009 Jul; 101(14):980-2. PubMed ID: 19584324
[No Abstract] [Full Text] [Related]
3. Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Green MR; Newton MD; Fancher KM
Am J Clin Oncol; 2016 Feb; 39(1):76-84. PubMed ID: 24351780
[TBL] [Abstract][Full Text] [Related]
4. Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
Tefferi A; Levitt R; Lasho TL; Knudson RA; Ketterling RP
Eur J Haematol; 2010 Jul; 85(1):86-7. PubMed ID: 20408872
[No Abstract] [Full Text] [Related]
5. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Ichim CV
Stem Cells Transl Med; 2014 Apr; 3(4):405-15. PubMed ID: 24598782
[TBL] [Abstract][Full Text] [Related]
6. Current treatment of myeloproliferative neoplasias: three scenarios.
Xicoy B; Zamora L
Med Clin (Barc); 2020 Feb; 154(4):131-133. PubMed ID: 31351663
[No Abstract] [Full Text] [Related]
7. Jakpot! New small molecules in autoimmune and inflammatory diseases.
Ghoreschi K; Gadina M
Exp Dermatol; 2014 Jan; 23(1):7-11. PubMed ID: 24131352
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Cornea MI; Levrat E; Pugin P; Betticher DC
J Med Case Rep; 2015 Apr; 9():30. PubMed ID: 26187587
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
Patterson H; Nibbs R; McInnes I; Siebert S
Clin Exp Immunol; 2014 Apr; 176(1):1-10. PubMed ID: 24313320
[TBL] [Abstract][Full Text] [Related]
10. Janus kinases: an ideal target for the treatment of autoimmune diseases.
Gadina M
J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S70-2. PubMed ID: 24326567
[TBL] [Abstract][Full Text] [Related]
11. The one-two punch: combination treatment in chronic myeloid leukemia.
Sweet KL; Hazlehurst LA; Pinilla-Ibarz J
Crit Rev Oncol Hematol; 2013 Dec; 88(3):667-79. PubMed ID: 23969231
[TBL] [Abstract][Full Text] [Related]
12. What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Deininger MW; Manley P
Leuk Res; 2012 Mar; 36(3):253-61. PubMed ID: 21996558
[TBL] [Abstract][Full Text] [Related]
13. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease.
Kontzias A; Kotlyar A; Laurence A; Changelian P; O'Shea JJ
Curr Opin Pharmacol; 2012 Aug; 12(4):464-70. PubMed ID: 22819198
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?
Beauverd Y; McLornan DP; Radia DH; Harrison CN
Future Oncol; 2016 Mar; 12(6):739-49. PubMed ID: 26846873
[TBL] [Abstract][Full Text] [Related]
15. New SRC/ABL inhibitors for chronic myeloid leukemia therapy show selectivity for T315I ABL mutant CD34(+) cells.
Santucci MA; Mancini M; Corradi V; Lacobucci I; Martinelli G; Botta M; Schenone S
Invest New Drugs; 2010 Dec; 28(6):876-8. PubMed ID: 19629392
[No Abstract] [Full Text] [Related]
16. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.
de Lavallade H; Khoder A; Hart M; Sarvaria A; Sekine T; Alsuliman A; Mielke S; Bazeos A; Stringaris K; Ali S; Milojkovic D; Foroni L; Chaidos A; Cooper N; Gabriel I; Apperley J; Belsey S; Flanagan RJ; Goldman J; Shpall EJ; Kelleher P; Marin D; Rezvani K
Blood; 2013 Jul; 122(2):227-38. PubMed ID: 23719297
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: BCR-ABL.
Cilloni D; Saglio G
Clin Cancer Res; 2012 Feb; 18(4):930-7. PubMed ID: 22156549
[TBL] [Abstract][Full Text] [Related]
19. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.
Lu XY; Cai Q; Ding K
Curr Med Chem; 2011; 18(14):2146-57. PubMed ID: 21517764
[TBL] [Abstract][Full Text] [Related]
20. [JAK2 inhibitors].
Hernández Boluda JC; Gómez M; Pérez A
Med Clin (Barc); 2016 Jul; 147(2):70-5. PubMed ID: 27033437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
